Deal Details

Lexeo Therapeutics, Inc. (“Lexeo”) (Nasdaq: LXEO) recently announced a private placement of 20,790,120 shares of its common stock at a price of $2.8825 per share and 6,963,556 pre-funded warrants at a price of $2.8824. Each full share and pre-funded warrant will be accompanied by a common warrant to purchase one-half of a share of common stock with an exercise price of $2.82 per share and an expiration date of May 28, 2029. Gross proceeds from the private placement will be approximately $80 million, before deducting placement agent commissions and offering expenses.

The financing was co-led by Frazier Life Sciences and Janus Henderson Investors with participation by new and existing investors, including Adar1 Capital Management, Affinity Healthcare Fund, LP, Ally Bridge Group, Coastlands Capital, Surveyor Capital (a Citadel company), Vestal Point Capital and Woodline Partners LP.

Baird served as a placement agent to Lexeo on this transaction.